Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05061693 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
A Phase 2 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT05061693 is a Phase 2 study of Prurigo Nodularis that has completed, run by Incyte Corporation. The registered enrollment target is 146 participants, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05061693, a Phase 2 study of Prurigo Nodularis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INCB054707
Study Locations (20)
Florida
- Investigative Site US019 - Fort Lauderdale
- Investigative Site US016 - Miami
- Investigative Site US013 - Miramar
- Investigative Site US009 - Tampa
Ohio
- Investigative Site US023 - Athens
- Investigative Site US002 - Dublin
- Investigative Site US012 - Gahanna
Arizona
- Investigative Site US010 - Phoenix
- Investigative Site US024 - Phoenix
California
- Investigative Site US001 - Fountain Valley
- Investigative Site US014 - Sacramento
Indiana
- Investigative Site US008 - Plainfield
- Investigative Site US011 - South Bend
Georgia
- Investigative Site 1071320 - Newnan
Maryland
- Investigative Site US003 - Baltimore
Michigan
- Investigative Site US017 - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2021-11-04 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05061693
The ClinicalTrials.gov registry entry for NCT05061693 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (33% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05061693 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT05061693 about?
NCT05061693 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis". The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
What is the current status of trial NCT05061693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2021-11-04. Estimated completion is 2024-02-28.
What conditions does trial NCT05061693 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT05061693?
The interventions under investigation include: Placebo (DRUG), INCB054707 (DRUG).
Who is sponsoring clinical trial NCT05061693?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05061693 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Barzolvolimab in Patients With Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of CC-10004 for Prurigo Nodularis
COMPLETED · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.